Nucleoside analogues are used to generate dose‐dependent DNA damage in malignant cells that then triggers p53‐dependent apoptosis (cytotoxicity). Normal dividing cells are unfortunately simultaneously destroyed. Therefore, to increase safety, nucleoside analogue doses are sometimes reduced, with an expected trade‐off of less cytotoxicity‐driven efficacy. Efficacy reduction with dose reduction may not apply, however, to the nucleoside analogue decitabine, because it has a molecular‐targeted action of depleting DNA methyltransferase 1 (DNMT1) that occurs, and is saturated at, low decitabine concentrations (generally \<1 μM). This molecular‐targeted action can cytoreduce p53‐null chemorefractory myeloid malignancies via terminal differentiation instead of apoptosis, simultaneously sparing normal haematopoiesis (Hu, *et al*, [2010](#bjh16281-bib-0004){ref-type="ref"}; Hu *et al.*, [2011](#bjh16281-bib-0005){ref-type="ref"}; Ng *et al.*, [2011](#bjh16281-bib-0009){ref-type="ref"}; Negrotto *et al.*, [2012](#bjh16281-bib-0008){ref-type="ref"}; Tsai *et al.*, [2012](#bjh16281-bib-0014){ref-type="ref"}; Gu *et al.*, [2014](#bjh16281-bib-0002){ref-type="ref"}; Saunthararajah *et al.*, [2015](#bjh16281-bib-0013){ref-type="ref"}; Gu *et al.*, [2018](#bjh16281-bib-0003){ref-type="ref"}; Velcheti *et al.*, [2018](#bjh16281-bib-0015){ref-type="ref"}). Higher decitabine doses/concentrations (generally \>1 μmol/l), by causing cytotoxicity, limit feasible exposure times for the S‐phase‐dependent DNMT1‐depleting effect, and can further compromise treatment goals by destroying normal haematopoietic cells. The initial clinical development of decitabine, however, was motivated by conventional cytotoxic intent; thus the regimens approved for treatment of myelodysplastic syndromes (MDS) administer relatively high doses (20--45 mg/m^2^/day) in pulses of 3--5 days every 4--6 weeks, intervals needed for recovery from cytotoxic side effects. To focus instead on a non‐cytotoxic, DNMT1‐targeting mode of action, we designed a decitabine regimen to avoid cytotoxicity and increase DNMT1 targeting, and describe here outcomes in 69 patients treated with this alternative decitabine regimen, 25 of whom were previously described with shorter follow‐up \[clinicaltrials.gov NCT00165996\]) (Saunthararajah *et al.*, [2015](#bjh16281-bib-0013){ref-type="ref"}).

The Cleveland Clinic Institutional Review Board‐approved Myeloid Malignancy Registry (16‐020) and Sample Repository protocols (5024) collected demographic, laboratory, intervention, outcome and mutational data in myeloid malignancy patients after written informed consent, intended to facilitate better understanding of natural histories, treatment selections and treatment outcomes in these patients; 69 of 1694 patients in the Registry received the alternative decitabine regimen between August 2008 and September 2018. All 69 patients are described in this analysis, followed from diagnosis till death or loss‐to‐follow‐up. All patient data were anonymized, and no patients were contacted to obtain any additional clinical or biological data for purposes of this report. The decitabine regimen‐modified dose, schedule and route of administration were as follows: (i) Dose: 0·1--0·2 mg/kg (\~3·5--5 mg/m^2^), verified to deplete DNMT1 without cytotoxicity in several primate and human studies (a 75--90% reduction from the FDA‐approved 20--45 mg/m^2^/day dose) (Saunthararajah *et al.*, [2003](#bjh16281-bib-0012){ref-type="ref"}; Olivieri *et al.*, [2011](#bjh16281-bib-0010){ref-type="ref"}; Lavelle *et al.*, [2012](#bjh16281-bib-0006){ref-type="ref"}; Saunthararajah *et al.*, [2015](#bjh16281-bib-0013){ref-type="ref"}). The starting dose of 0·2 mg/kg was reduced to 0·15 mg/kg if infection risk was high \[e.g. absolute neutrophil count (ANC) \<0.5 × 10^9^/l\]. (ii) Schedule: 1--2×/week, frequent and distributed, to increase S‐phase‐dependent DNMT1 depletion (contrasting with standard pulse‐cycled administration for 3--5 days every 4--6 weeks). Frequency of administration was adjusted based on disease aggression and response: for example, 2×/week on consecutive days for myeloblasts \>10%, or for lack of response to 1×/week administration. (iii) Route: subcutaneous, to avoid high peak concentrations (contrasting with approved regimens that infuse decitabine intravenously over 60 min). Neutropenia caused by treatment was managed by interruption until neutrophil count recovery then resumption at the same dose or with a dose lowered by 0·05 mg/kg. Routine anti‐emetic prophylaxis was not required.

Non‐cytotoxic DNMT1‐depletion was confirmed by bone marrow γH2AX and DNMT1 measurements in an initial 25 patients treated (these results were previously published; Saunthararajah *et al.*, [2015](#bjh16281-bib-0013){ref-type="ref"}). The 69 patients had MDS (*n* = 37, 54%), MDS/MPN (myeloproliferative neoplasms; *n* = 10, 14%), MPN (*n* = 12, 17%) and AML (acute myeloid leukaemia; *n* = 10, 15%) (Fig [1](#bjh16281-fig-0001){ref-type="fig"}A, Table [1](#bjh16281-tbl-0001){ref-type="table"}; Table [SI](#bjh16281-sup-0001){ref-type="supplementary-material"}). Their median age was 69 years (range 45--89), 19 were female, and 50 were male (Table [1](#bjh16281-tbl-0001){ref-type="table"}; Table [SI](#bjh16281-sup-0001){ref-type="supplementary-material"}). Prior therapies (53/69, 77%) were 5‐azacytidine (20/69, 29%), lenalidomide (14/69, 20%), erythropoietin (18/69, 26%), hydroxycarbamide (5/69, 7%), ruxolitinib (5/69, 7%), and cytarabine (3/69, 4%) (Fig [1](#bjh16281-fig-0001){ref-type="fig"}A, Table [1](#bjh16281-tbl-0001){ref-type="table"}; Table [SI](#bjh16281-sup-0001){ref-type="supplementary-material"}). The side‐effect was neutropenia (non‐cytotoxic DNMT1 depletion skews myeloid differentiation away from granulocyte‐monocyte progenitors and toward erythrocyte‐megakaryocyte progenitors (Saunthararajah *et al.*, [2003](#bjh16281-bib-0012){ref-type="ref"}; Milhem *et al.*, [2004](#bjh16281-bib-0007){ref-type="ref"}) (Figure [S1](#bjh16281-sup-0001){ref-type="supplementary-material"}), complicated by fever/infection in 31 patients (45%), with one septic death. Blood count improvements meeting International Working Group (IWG) criteria (Cheson *et al.*, [2006](#bjh16281-bib-0001){ref-type="ref"}) for response \[haematologic improvement (HI)/complete remission (CR)\] occurred in 30 patients (HI/CR 43%: HI 29%, CR 14%; Fig [1](#bjh16281-fig-0001){ref-type="fig"}A, Tables [1](#bjh16281-tbl-0001){ref-type="table"} and [2](#bjh16281-tbl-0002){ref-type="table"}) and were durable \[median response duration was 48 weeks (range 8--326); type of response and duration are summarized in Table [2](#bjh16281-tbl-0002){ref-type="table"}\]. Patients not meeting criteria for HI or CR met IWG criteria for stable disease (SD; 30/69, 44%) or progressive disease (PD; 9/69, 13%) (Table [SI](#bjh16281-sup-0001){ref-type="supplementary-material"}). Responses (HI/CR) were seen in different histologic subtypes of myeloid malignancy \[MDS 14/37 (38%), MDS/MPN 8/10 (80%), MPN 4/12 (33%), AML 4/10 (40%)\], and in patients previously treated with 5‐azacytidine (7/20, 35%), lenalidomide (5/14, 36%), or cytarabine (1/3, 33%; Fig [1](#bjh16281-fig-0001){ref-type="fig"}A, Table [1](#bjh16281-tbl-0001){ref-type="table"}). Cytogenetics were normalized in 10/36 (28%) cases with abnormal karyotypes at baseline (Table [1](#bjh16281-tbl-0001){ref-type="table"}, Fig [1](#bjh16281-fig-0001){ref-type="fig"}B) (chromosome Y deletion was considered a normal age‐related change and not considered abnormal). Treatment decreased bone marrow myeloblasts, even in cases not meeting IWG criteria for response (Fig [1](#bjh16281-fig-0001){ref-type="fig"}C). Patients with HI/CR had better overall survival (median 31 vs. 18 months; *P* = 0·036; Fig [1](#bjh16281-fig-0001){ref-type="fig"}D). HI/CR was achieved in MDS/AML containing monosomy 7, trisomy 8, complex cytogenetic abnormalities and/or multiple mutations including in kinases (e.g. *JAK2*, *KRAS*, *FLT3*), epigenetic regulators (e.g. *TET2*, *DNMT3A*, *ASXL1*), splicing factors (e.g. *SF3B1*, *ZSRS2*, *SRSF2*), apoptosis regulators (e.g. *TP53*), transcription factors (e.g. *RUNX1*, *CEBPA*), and other genes (e.g. *NPM1*, *IDH1*, *IDH2*; Table [1](#bjh16281-tbl-0001){ref-type="table"}; Table [SIII](#bjh16281-sup-0001){ref-type="supplementary-material"}). Predictors of HI/CR were higher baseline neutrophils (median 3·04 × 10^9^/l vs. 1·17 × 10^9^/l; *P* = 0·002), higher baseline marrow cellularity (median 70%/ vs. 45%; *P* = 0·03) and higher baseline reticulocytes (56 × 10^9^/L vs. 46 × 10^9^/L; *P* = 0·03; Fig [1](#bjh16281-fig-0001){ref-type="fig"}D, E) (Table [SII](#bjh16281-sup-0001){ref-type="supplementary-material"}, Fig [1](#bjh16281-fig-0001){ref-type="fig"}E, F). Bone marrow myeloblasts, and other clinical phenomena such as Sweet's syndrome and/or granulocytic sarcomas, were improved by therapy even in patients with blood count changes that did not meet IWG criteria for response (HI/CR; Fig [1](#bjh16281-fig-0001){ref-type="fig"}C). Such benefits, and improvements in blood counts even if these did not meet criteria for response (Figure [S2](#bjh16281-sup-0001){ref-type="supplementary-material"}), motivated extended treatment in some patients classified as non‐responders: median treatment duration in patients with stable disease was 34 weeks (range 13--260), and 12 weeks (range 3--20) in patients with progressive disease.

![(A) Response (haematologic improvement or complete remission \[HI/CR\]) *versus* non‐response \[stable disease or progressive disease (SD/PD)\] in patients grouped by myeloid malignancy sub‐type and previous 5‐azacytidine (5Aza), lenalidomide or cytarabine (AraC) therapy. (B) Change in abnormal metaphases on therapy \[(abnormal metaphases on treatment − pretreatment)/pretreatment ×100\]. Only cases with both on‐treatment and pretreatment karyotype analyses shown. (C) Change in the bone marrow myeloblast percentage on therapy (best response myeloblasts% on‐treatment − pretreatment myeloblasts%). Only cases with pretreatment (with this decitabine regimen) myeloblasts ≥5% together with on‐treatment bone marrow myeloblast data available shown. (D) Overall survival, stratified by responders and non‐responders. (E) Pretreatment bone marrow cellularity. Lines, Median ± interquartile range (IQR); *P*‐value, Wilcoxon test, two‐sided, HI/CR *versus* SD/PD. (F) Pretreatment absolute neutrophil counts (ANC;×10^9^/l) by response *versus* non‐response within each disease subtype. Lines, Median ± IQR; *P*‐value, Wilcoxon test, two‐sided, HI/CR *versus* SD/PD](BJH-188-924-g001){#bjh16281-fig-0001}

###### 

Pretreatment characteristics of patients with blood count changes meeting International Working Group criteria for response (HI/CR).

  Age/Sex      WHO classification 2016   Previous treatments       Gene mutations (selected)                   Pretreatment blast %   On‐treatment blast %   Pretreatment cytogenetics   On‐treatment cytogenetics   Haematologic response (IWG[\*](#bjh16281-note-0002){ref-type="fn"})
  ------------ ------------------------- ------------------------- ------------------------------------------- ---------------------- ---------------------- --------------------------- --------------------------- ---------------------------------------------------------------------
  Responders                                                                                                                                                                                                         
  69/M         PMF                       Pred, IVIg,Thal           *JAK2*                                      1                      1                      ND                          Normal                      HI
  86/M         MDS‐SLD                   None                      ND                                          0                      1                      Normal                      ND                          CR
  79/F         MDS‐MLD                   Rom                       None                                        1                      1                      del(20)                     del(20)                     HI
  73/M         CMML2                     Len                       *JAK2*                                      12                     0                      del(20)                     Normal                      CR
  64/M         Post‐PV MF                Ima, Rux                  *JAK2*                                      3                      2                      Complex                     Complex                     HI
  66/M         MDS‐RS‐MLD                Len, 5‐aza                *SF3B1*                                     2                      1                      −Y                          −Y                          HI
  65/M         MDS‐MLD                   Epo                       None                                        3                      0                      Complex                     Normal                      CR
  67/F         MDS‐EB1                   Vcr, Dox, Mel             None                                        6                      4                      Complex                     Normal                      HI
  58/M         CMML1                     None                      *TET2, ZRSR2*                               2                      0                      Normal                      +1,t(1;15)                  CR
  86/M         PMF                       Dan                       Not Done                                    0                      ND                     ND                          ND                          HI
  66/M         CMML1                     None                      *KRAS, SRSF2, TET2*                         4                      0                      +mar\[2/20\]                Normal                      CR
  61/M         MDS‐EB2                   Len                       *FLT3*                                      2                      0                      Complex                     Normal                      CR
  83/F         MDS‐EB1                   Epo                       *BCOR, CEBPA, DNMT3A, RUNX1, SRSF2, TET2*   9                      3                      Normal                      Normal                      HI (marrow CR)
  69/M         CMML1                     None                      *BCOR, CBL, PRPF8, RUNX1, SRSF2, TET2*      2                      1                      Normal                      Normal                      HI
  89/M         sAML                      Cyt, 5‐aza                *SF3B1*                                     11                     ND                     ‐Y                          ‐Y                          HI
  69/M         PMF                       5‐aza                     None                                        5                      3                      del(20)                     del(20)                     HI
  67/M         MDS‐MLD                   None                      *TET2*                                      2                      ND                     del(13)                     ND                          HI
  58/M         MDS‐U                     5‐aza                     *ASXL1, IDH1, RUNX1, ZRSR2*                 0                      2                      del(11)                     del(11)                     HI
  86/M         MDS‐MLD                   Epo, Eltrom               ND                                          1                      ND                     del(20)                     ND                          CR
  52/F         MDS‐RS‐SLD                Epo, G‐CSF                None                                        2                      4                      Normal                      Normal                      CR
  78/F         MDS‐MLD                   Pred                      *NRAS, TP53*                                1                      1                      Complex                     Normal                      CR
  69/M         CMML1                     Len, Epo                  *BCOR, ETV6, EZH2, U2AF1*                   2                      4                      Normal                      Normal                      HI
  77/F         aCML                      Rux, Hyd                  *SETBP1, SF3B1, SRSF2*                      0                      ND                     Normal                      Not Done                    HI
  70/F         sAML                      Lef                       *IDH2, NPM1, SRSF2, TET2*                   80                     3                      del(4)                      Normal                      HI (marrow CR)
  81/M         CMML1                     Niv                       *CUX1, SRSF2, TET2*                         1                      ND                     Normal                      Normal                      HI
  68/M         sAML                      None                      *JAK2*                                      26                     2                      −7                          −7                          HI (marrow CR)
  71/M         MDS‐MLD                   ESA, G‐CSF, Len, 5‐aza,   *IDH1, NPM1, PHF6, U2AF1*                   0                      ND                     Complex                     ND                          HI
  61/M         CMML2                     5‐aza, Epo                *ASXL1, IDH2, JAK2, RUNX1, STAG2*           10                     ND                     Normal                      ND                          CR
  81/F         MDS‐MLD                   Rom                       None                                        2                      0                      del(20)                     del(20)                     HI
  75/M         sAML                      5‐aza                     ND                                          1                      ND                     Normal                      ND                          HI

MDS, myelodysplastic syndrome; MDS‐U, MDS unclassified; MDS‐SLD, MDS with single lineage dysplasia; MDS‐MLD, MDS with multilineage dysplasia; MDS‐EB1, MDS with with excess blasts (blasts make up 5--9% of the cells in the bone marrow, or 2--4% of the cells in the blood); MDS‐EB2, MDS with with excess blasts (blasts make up 10--19% of the cells in the bone marrow, or 5--19% of the cells in the blood); MDS‐RS‐SLD, MDS with ring sideroblasts with single lineage dysplasia; MDS‐RS‐MLD, MDS with ring sideroblasts with multilineage dysplasia; CMML, chronic myelomonocytic leukemia; PMF, primary myelofibrosis; Post‐PV MF, post--polycythaemia vera myelofibrosis; aCML, atypical chronic myeloid leukemia; sAML, secondary acute myeloid leukemia; 5‐aza, azacitidine; Len, lenalidomide; Mel, melphalan; Rom, romiplostim; Rux, ruxolitinib; Ima, imatinib; Hyd, hydroxycarbamide; Cyt, cytarabine; Dan, danazol; Eltrom, eltrombopag; Lef, leflunomide; Niv, nivolumab; Epo, erythropoietin or darbepoietin; Vcr, vincristine; Dox, doxorubicin; Pred, prednisone; IVIg, Intravenous immunoglobulin; G‐CSF, granulocyte‐colony stimulating factor; Thal, thalidomide. M, male; F, female; ND, not done; HI, haematologic improvement; CR, complete remission; WHO, World Health Organization.

International Working Group (IWG) 2006 Criteria for Response in MDS Clinical Trial.
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###### 

Type and duration of response in patients meeting International Working Group criteria for haematologic response (HI/CR)

  Case                                      Haematologic response (IWG)   Haematological improvement   CR                                                 
  ----------------------------------------- ----------------------------- ---------------------------- -------------- ------------- ---- ----- ---- ----- -----
  1                                         HI                            E, P                         \+             89                                   
  2                                         CR                            P                                                         \+   30               9
  3                                         HI                            E, P                         \+             321           \+   326               
  4                                         CR                            E, P, N                      \+             36            \+   147   \+   160   52
  5                                         HI                            P                                                         \+   74                
  6                                         HI                            E                            \+             28                                   
  7                                         CR                            E, P, N                      \+             49            \+   42    \+   42    40
  8                                         HI                            E, P                         \+             62            \+   145               
  9                                         CR                            N                                                                    \+   12    12
  10                                        HI                            E, P                                                      \+   66                
  11                                        CR                            E                            \+             133                                 133
  12                                        CR                            E, P                         \+             43            \+   178              36
  13                                        HI                            P                                                         \+   11                
  14                                        HI                            E, P                         \+             41                                   
  15                                        HI                            E, N                         \+             53                       \+   14     
  16                                        HI                            E, P                         \+             47                                   
  17                                        HI                            E, P, N                                                   \+   31    \+   15     
  18                                        HI                            E                            \+             30                                   
  19                                        CR                            P                                                         \+   44               18
  20                                        CR                            E                            \+             89                                  86
  21                                        CR                            E, P                         \+             41            \+   35               28
  22                                        HI                            E, P                         \+             30            \+   53                
  23                                        HI                            E, P                         \+             24                                   
  24                                        HI                            E, P                         \+             28            \+   14                
  25                                        HI                            E, P                                                      \+   8                 
  26                                        HI                            E, P                                                      \+   8                 
  27                                        HI                            E, P, N                                                   \+   20                
  28                                        CR                            E, P                         \+             79            \+   58               10
  29                                        HI                            P, N                                                                 \+   155    
  30                                        HI                            E, P                         \+             48            \+   51                
  Response duration, median (range) weeks   47 (24--321)                  44 (8--326)                  15 (12--160)   32 (9--133)                         

Baseline cytopenias: E = haemoglobin \<110 g/l or transfusion dependent; P = platelets \<100 × 10^9^/l; N = neutrophils \<1 × 10^9^/l. Erythroid response: Hgb increase by ≥15 g/l for \>8 weeks or transfusion reduction per IWG criteria. Platelet response: increase from \<20 to \>20 × 10^9^/l and by at least 100%, or increase of ≥30 × 10^9^/l if baseline is \>20 × 10^9^/l, for \>8 weeks. Neutrophil response: at least 100% increase and an absolute increase \>0·5 × 10^9^/l for \>8 weeks. IWG, International Working Group; CR, complete remission; w, weeks; +, response achieved.

John Wiley & Sons, Ltd

Thus, a decitabine regimen designed and previously demonstrated to be non‐cytotoxic yet DNMT1‐depleting in non‐human primates and humans (Saunthararajah *et al.*, [2003](#bjh16281-bib-0012){ref-type="ref"}; Olivieri *et al.*, [2011](#bjh16281-bib-0010){ref-type="ref"}; Lavelle *et al.*, [2012](#bjh16281-bib-0006){ref-type="ref"}; Saunthararajah *et al.*, [2015](#bjh16281-bib-0013){ref-type="ref"}) produced durable responses (follow‐up was for up to 6·5 years) in myeloid malignancies across the clinico‐pathologic spectrum of disease --- that is, in patients with MDS, MDS/MPN overlap, MPN or AML and in disease containing diverse genetic abnormalities --- consistent with scientific data implicating DNMT1 as a mutation‐agnostic target that operates in a final common pathway of myeloid transformation (Hu *et al.*, [2010](#bjh16281-bib-0004){ref-type="ref"}; Hu *et al.*, [2011](#bjh16281-bib-0005){ref-type="ref"}; Ng *et al.*, [2011](#bjh16281-bib-0009){ref-type="ref"}; Negrotto *et al.*, [2012](#bjh16281-bib-0008){ref-type="ref"}; Gu *et al.*, [2014](#bjh16281-bib-0002){ref-type="ref"}; Saunthararajah *et al.*, [2015](#bjh16281-bib-0013){ref-type="ref"}; Gu *et al.*, [2018](#bjh16281-bib-0003){ref-type="ref"}; Velcheti *et al.*, [2018](#bjh16281-bib-0015){ref-type="ref"}). Likewise, a broad spectrum of activity has been observed with standard intravenously infused regimens of decitabine \[reviewed in [Saunthararajah](#bjh16281-bib-0011){ref-type="ref"}([2013](#bjh16281-bib-0011){ref-type="ref"})\]. We postulate that target validity and avoidance of cytotoxicity enabled the sustained disease control/transfusion freedom observed in several patients treated with the present regimen, some of whom were \>80 years old. Reported links by others between some mutations, for example, in *TET2*, and response to decitabine could be via higher neutrophils (*TET2* mutations are also linked with high white cell counts) that in turn enable on‐time, regular exposures to this S‐phase‐dependent therapeutic \[reviewed in Saunthararajah *et al.* ([2015](#bjh16281-bib-0013){ref-type="ref"})\] --- the main side‐effect of DNMT1‐depletion is a shift in myeloid differentiation toward erythroid‐megakaryocyte progenitors and away from granulocyte‐monocyte progenitors, thereby depressing neutrophil counts, a shift that is more likely to interrupt or delay treatment exposures if neutrophil counts are low to begin with. Another fundamental is that haematologic response (HI/CR) requires not just suppression of malignant clones but marrow capacity to regenerate and support functional haematopoiesis --- low baseline marrow cellularity that suggests compromise to such capacity is therefore linked with lack of haematologic response, even though malignant clones may be suppressed by therapy as shown by decreasing bone marrow myeloblasts and fewer abnormal metaphases (Saunthararajah, [2013](#bjh16281-bib-0011){ref-type="ref"}).

Other "low‐dose" decitabine regimens have been evaluated, although some are more accurately described as "low‐frequency" since they administer potentially cytotoxic doses less often (e.g., 20 mg/m^2^/day for three instead of five consecutive days every four weeks) --- the overall response rate (HI/CR) with subcutaneous decitabine 20 mg/m^2^/day for three days every four weeks was 23% (*n* = 65) and with decitabine 20 mg/m^2^/day infused over 1 h for three days every four weeks was 70% (*n* = 73), with both trials treating previously untreated low/intermediate‐risk MDS patients (Table [SIV](#bjh16281-sup-0001){ref-type="supplementary-material"}). By contrast, the response rate here was \~40%, even though approximately 50% of the patients had disease that was relapsed/refractory to 5‐azacytidine, lenalidomide and/or cytarabine, and approximately 25% of them had pretreatment bone marrow myeloblasts of ≥10% (Table [SIV](#bjh16281-sup-0001){ref-type="supplementary-material"}). There remains a need to address mechanisms of resistance to decitabine (and 5‐azacytidine), and in addition, a need for separate measures to simultaneously support regeneration by functional haematopoiesis, since in this mostly elderly patient population such capacity is diminished by age, disease and previous cytotoxic treatments.
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**Table SI.** Characteristics of patients with blood count changes not meeting IWG criteria for response.

**Table SII.** Baseline characteristics of responders *versus* non‐responders (patients meeting *versus* not meeting IWG criteria for response).

**Table SIII.** Genes sequenced (targeted sequencing panel).

**Table SIV.** Summary of results of clinical trials evaluating decitabine to treat myelodysplastic syndrome (MDS).

**Fig S1.** Serial blood counts (first 52 weeks shown only) in all patients by International Working Group (IWG) response *versus* non‐response (haemoglobin in g/l, platelet in 10^9^/l and absolute neutrophil count (ANC) in 10^9^/l).

**Fig S2.** Serial blood counts in patients not meeting International Working Group (IWG) criteria for response but with long‐term stability or small improvements on therapy.
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